- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Radiation for Hodgkin’s disease puts women at greater risk for breast cancer
Women exposed to radiation therapy for Hodgkin’s disease have a relative risk 7.7 times greater than the general population of developing breast cancer, according to a study presented at the European Congress of Radiology in Vienna, in March.
Women exposed to radiation therapy for Hodgkin’s disease have a relative risk 7.7 times greater than the general population of developing breast cancer, according to a study presented at the European Congress of Radiology in Vienna, in March.
European Congress of Radiology in Vienna, in March. Dr. Andrea Luparia, from the University of Torino in Italy, and colleagues retrospectively studied 43 women treated with radiation therapy for Hodgkin’s disease between 1980 and 2009. Six invasive breast cancers were detected by mammography in five of the 43 women. Breast cancer was diagnosed following a median latent period from radiotherapy of 13.3 years. Average radiation dose was 33.6 Gy while in women who developed breast cancer it was 37.9 Gy.
For women treated for Hodgkin’s disease with radiation therapy, no-dose breast imaging options should be considered, the authors said. Of women with high-density breasts, those younger than 30 should be monitored with ultrasound and MR. Those older than 30 should be monitored with ultrasound, mammography, and MR.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.
FDA Clears New Features in AI-Powered Mammography Software Suite
October 11th 2024Therapixel’s MammoScreen suite has received 510(k) FDA clearances for a breast density assessment feature and updated software that includes automated pre-reporting, which reportedly expedites reporting of mammography findings.
